Th e syn t h e sis o f a series o f α-L-2'-deoxythreofuranosyl nucleosides featuring the nucleobases A, T, C and U is described in seven steps from 1,2-O-isopropyledene-α-Lthreose, involving a Vorbrüggen coupling and a Barton-McCombie deoxygenation protocol as the key steps. All analogues, including a phosphoramidate nucleoside phosphate prodrug of the T analogue, were evaluated against a broad panel of different viruses but found inactive, while also lacking notable cellular toxicity. The thymidine analogue showed inhibition to mitochondrial thymidine kinase-2 (TK-2), herpes simplex virus type 1 (HSV-1) TK, varicella-zoster virus (VZV) TK and M. tuberculosis thymidylate kinase.
Introduction
The human immunodeficiency virus (HIV) epidemic has fostered research on antiviral drugs both in academia and industry [1] . Although preventive vaccines are available for a number of viral diseases, the chances of successfully developing a safe and effective vaccine for HIV and hepatitis C virus (HCV) in the near future looks very uncertain [2] .
Recently, Herdewijn and coworkers showed that selected L-2-deoxythreose nucleoside phosphonates (I; Figure 1 ) selectively inhibit HIV without affecting human DNA synthesis [6] . PMDTA (Ia) and PMDTT (Ib) lack a hydroxymethyl group at the 4'-position of the furanose ring, but instead have a phosphonomethyl ether moiety at the 3'-position, which mimicks the monophosphate ester of a 3'-hydroxymethyl substituent.
Structural modifications on either the sugar or base moiety of natural nucleosides has resulted in a series of 24 nucleoside or nucleotide analogues licensed as drugs against various viral infections, such as herpes simplex virus (HSV), human cytomegalovirus (HCMV), varicella zoster virus (VZV), HIV-1, human hepatitis B virus (HBV) and HCV [3] [4] [5] . Despite this achievement, continued efforts toward the discovery of new nucleoside-based antivirals are required to overcome common problems in antiviral chemotherapy, such as toxicity, adverse effects, drug-drug interactions and, last but not least, the development of drug resistance.
These nucleoside analogues require two additional phosphorylation steps by cellular kinases before they are incorporated in the viral genome and lead to chain termination of the proviral DNA strand during the reverse transcription process.
By synthesizing and evaluating the isomeric analogues of PMDTA, the importance of the relative (cis) and absolute orientation of the substituents at the 1' and 3 '- showed that (L)-α-threofuranosyl oligonucleotides (TNAs) containing vicinally connected (3' →2') phosphodiester bridges undergo informational base pairing in antiparallel strand orientation and are capable of cross-pairing with RNA and DNA [7] .
Inspired by the promising anti-HIV-1/HIV-2 activity of Ia-b, we decided to explore the synthesis and the antiviral properties of the corresponding non-phosphonylated 2-deoxythreose-based nucleoside analogues II, characterized by a four-carbon-only carbohydrate part. We expected that due to the absence of the 4'-hydroxymethyl group, the secondary 3'-OH could become accessible for phosphorylation by cellular nucleoside kinases and anticipated IIa-d to have a superior bioavailability compared to the phosphonates. Remarkably, the synthesis of such α-L-2'-deoxythreofuranosyl analogues (exhibiting the 1'R, 3'R configuration) has not been reported before.
Results and Discussion

Chemical Synthesis
The synthesis of target compounds started from 1,2-O-isopropyledene-α-L-threose 1 (Scheme 1), which was synthesized in multi-gram scale following literature procedures [8, 9] . The hydroxyl group of 1 was protected using either benzyl bromide or 4-methoxybenzyl (PMB) chloride to give compounds 2 and 3 in excellent yields. A benzyl group is a safe and versatile protecting group for carbohydrates, but may require harsh deprotection conditions. We also explored a more sensitive PMB protecting group, which may be removed under alternative conditions. Next, deprotection of the isopropylidene group upon treatment with 80% aq. acetic acid followed by acetylation afforded the key precursors 4 and 5 in good yield.
A Vorbrüggen coupling reaction of 4 and 5 with the preformed silyl-protected nucleobases exclusively gave the α-nucleosides 6-11 due to anchimeric assistance from the 2-O-acetyl group [10] . The benzyl-protected thymine-and uracil-nucleosides 6 and 7 were isolated in considerably better yields than the PMB protected analogues, due to instability of the PMB-protecting group under Vorbrüggen conditions. Moreover, the reaction between PMB-protected glycon 5 with silylated N 6 -benzoyladenine and N 4 -acetylcytosine failed to produce the desired coupling products in acceptable yields, which forced us to restrict further investigations to the benzyl-protected nucleosides. Under normal coupling conditions, the yield of the adenine coupling product 10 was also very low, possibly due to the formation of other isomers [11] . However, prolonged reaction time at elevated temperature (50 °C) afforded the thermodynamically favored isomer 10 in an acceptable yield of 42%. Under the normal coupling conditions the cytidine analogue 11 was obtained in 70 % yield.
The 2'-O-acetyl group of 6 and 7 was removed by treatment with 7N ammonia in methanol. Similar treatment of 8 and 9 led to the formation of small amounts of 2',3'-dihydroxy analogues (10-15%). Lowering the ammonia concentration to 1N allowed to obtain the desired compounds 14 and 15 in high yields. Stirring compound 10 at room temperature in a 7N solution of ammonia in methanol for 2 days removed both the 2'-Oacetyl and the N(6)-benzoyl group to yield 16. Likewise, 11 was deprotected to the dideacetylated compound 17, which was selectively N-acylated to 18 with one equivalent of acetic anhydride in dimethylformamide [12] .
Deoxygenation of the 2'-hydroxy group was realized following a two step BartonMcCombie procedure [13] . The xanthate was formed by reacting the 2'-OH group of 12-16 and 18 with p-tolyl chlorothionocarbonate in the presence of 4-dimethylaminopyridine.
The intermediate formed was subjected to heating with tributyltinhydride and azoisobisbutyronitrile in toluene to give the 2'-deoxygenated compounds 19-24 in moderate to good yields (47-86%).
All target compounds were obtained after debenzylation. However, optimal debenzylation procedures were distinct for each analogue. The 2'-deoxythreose thymine and uracil analogues 25 and 26 could be obtained by catalytic hydrogenation of 19 and 20 in good albeit variable yields, possibly due to catalyst poisoning by the residual sulphur from the previous deoxygenation reaction. Desulphurization with hydrogen over RaneyNickel prior to palladium-catalysed debenzylation improved the reproducibility of this step. Alternatively, CAN-mediated deprotection [14] of 21 and 22 afforded 25 and 26, respectively. The adenine analogue 27 was obtained by a palladium-catalysed hydrogenation reaction in moderate yields.
The cytosine analogue 29 was obtained via two different routes. After an unsuccessful attempt to hydrogenate 24, the benzyl group was removed by treatment with excess of dichlorodicyanoquinone (DDQ) in dichloromethane at 50 °C in a sealed reaction vial for 3 days [15] . This method gave 28 in a disappointing yield of 11%. Hence, we also explored the transformation of the uridine analogue 26 to compound 29 (Scheme 2) [16] .
This was realized by protecting the 3'-hydroxy group of 26 to the corresponding acetate 30, which was subsequently treated with phosphorous oxychloride and 1,2,4-triazole, bubbling ammonia gas and a 7N solution of ammonia in methanol.
The coupling between the phenyldichlorophosphate (31) and L-alanine benzyl ester tosylate (32) has been performed in the presence of Et 3 N (2 eq) giving the desired product (33) as an oil, which was used in the following step as a crude (Scheme 3). The final coupling of the nucleoside 25 has been performed using an excess of the phosphorochloridate (33) (3 eq) in the presence of t BuMgCl (3eq) following the procedure reported by Uchiyama [17] and extensively used for the synthesis of the ProTides [18] . The desired compound 34 was obtained as a mixture of two diastereoisomers confirmed by the presence of two peaks in the 31 P NMR (2.92, 2.27).
Pharmacological Activity
None of the final nucleoside analogues showed cytotoxicity at 100 µg/mL. No anti-HIV-1 and anti-HIV-2 activity was observed in human T-lymphocyte (CEM) cells (EC50 >100 µg/mL). Furthermore, no significant activity could be detected against the Enzymatic study using carboxypeptidase Y enzyme.
The first step of the bioactivation of the phosphoramidate ProTide moiety involves the hydrolysis of the ester moiety which is supposed to be mediated by a carboxypeptidasetype enzyme (Scheme 4). An enzymatic study using carboxypeptidase Y enzyme has been performed in order to understand whether compound 34 may be metabolized under these conditions.
The experiment was performed by incubating compound 34 with carboxypeptidase in acetone-d 6 and trizma buffer (pH = 7.6) following its conversion by 31 P-NMR. The spectra ( Figure 2 ) showed a fast conversion of one of the diasteroisomers 34 (δ P = 2.38)
to the compound 37 (δ P = 6.25) through the intermediate 35 (δ P = 3.66). The other diastereoisomer (δ P = 2.24) was slower converted and it was still detectable after 14 h.
This experiment showed that 34 is partially converted to the metabolite 37.
Interaction of test compounds with nucleoside kinases.
Interestingly, upon evaluation of their capacity to inhibit thymidine (1 µM) phosphorylation by recombinant purified human cytosolic TK1, human mitochondrial TK2, HSV-1 TK, VZV TK, and Drosophila melanogaster (Dm) dNK (Table 1) , compound 25 proved inhibitory to TK-2, HSV-1 TK, and VZV TK at an IC 50
In conclusion, we have developed a practical and straightforward procedure for the synthesis of a series of α-L-2'-deoxythreofuranosyl nucleosides containing four natural nucleobases. None of the analogues displayed significant antiviral activity or cytotoxicity.
In an effort to bypass the first activation (phosphorylation) step of the nucleoside ranging between 14 and 91 µg/mL and M. tuberculosis thymidylate kinase with a Ki of 18 µM.
Therefore, compound 25 was investigated more in detail. Whereas 75% of the natural substrate thymidine (100 µM) was converted to its 5'-mono-(and 5'-di)phosphate within 5 minutes upon exposure to HSV-1 TK, no signs of any conversion of compound 25 to its phosphorylated derivative was observed after 60 minutes of incubation with the enzyme.
Therefore, we may assume that these nucleosides purely act as enzyme inhibitors, rather than acting as alternative substrates. Lineweaver-Burk kinetic analysis revealed a noncompetitive mechanism of inhibitory action of compound 25 against HSV-1 TK using dThd as the natural substrate ( Figure 3 ). The inhibitory potential of some of the test compounds opens perspectives for using this L-α-2'-deoxythreofuranosyl ring as a scaffold for optimizing these enzyme inhibitory activities.
analogues, a phosphoramidate nucleoside phosphate prodrug was synthesized for compound 25, but this prodrug still lacked any measurable antiviral activity. However, the thymine analogue showed encouraging inhibitory activity towards a number of thymidine kinases, which may be a new starting point towards more potent and selective nucleoside kinase inhibitors.
Experimental Section Chemical Synthesis
All reagents were from standard commercial sources and of analytic grade. Dry solvents were obtained directly from commercial sources and stored on molecular sieves. and the mixture was stirred for 10 minutes. Benzyl bromide (2.56 mL, 21.54 mmol) was added dropwise to the above suspension, which was allowed to come to room temperature and stirred for an additional 4h. The reaction mixture was quenched by addition of methanol (1 mL) and the volatile solvents were evaporated under reduced pressure. The residue was partitioned between water-ethyl acetate (1:3, 300 mL). The organic layer was separated, washed with water, brine and dried over anhydrous MgSO 4 .
After evaporation, the crude product was purified by silica-gel chromatography (15% 
1-((2R,3R,4S)-4-(4-methoxybenzyloxy)-tetrahydro-3-hydroxyfuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (14
(2R,3R,4S)-2-(6-amino-9H-purin-9-yl)-4-(benzyloxy)-tetrahydrofuran-3-ol (16).
Nucleoside 10 (680 mg, 
4-amino-1-((2R,3R,4S)-4-(benzyloxy)-tetrahydro-3-hydroxyfuran-2-yl)pyrimidin-
2(1H)-one (17).
N-(1-((2R,3R,4S)-4-(benzyloxy)-tetrahydro-3-hydroxyfuran-2-yl)-1,2-dihydro-2-oxopyrimidin-4-yl)acetamide (18
1-((2R,4R)-4-(benzyloxy)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (19
1-((2R,4R)-4-(benzyloxy)-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (20).
1-((2R,4R)-4-(4-methoxybenzyloxy)-tetrahydrofuran-2-yl)-5-methylpyrimidine-
2,4(1H,3H)-dione (21).
9-((2R,4R)-4-(benzyloxy)-tetrahydrofuran-2-yl)-9H-purin-6-amine (23).
Deoxygenation 
Enzymatic Assay
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29 >200 >200 >200 >200 >200 Scheme 4. Putative mechanism of bioactivation of the ProTide. 
